Browse By Topic: Diabetes and diabetic retinopathy

Diabetic retinopathy occurs when diabetes damages the tiny blood vessels in the retina. Learn more about diabetes and diabetic retinopathy, as well as other eye conditions that can cause low vision: age-related macular degeneration, macular hole, cataracts, glaucoma and retinitis pigmentosa. You can also find helpful tips and techniques for everyday living skills and reading and writing, along with helpful products and low vision devices. Register to receive alerts and news relating to vision loss, including the latest updates in medical research.

Our Readers Want to Know: What Does It Mean When My Eye Doctor Tells Me I Have "Low Vision"?

Editor's note: One of the many benefits associated with an online information center and website, such as VisionAware, is the ability to track readers' search terms [i.e., information readers are seeking as they search online]. Of particular concern to many readers are issues related to the diagnosis and treatment of low vision, as evidenced by the following searches: I've been told I have low vision, but what does this mean? How is low vision different from blindness? Is there a cure for low vision? An Answer from VisionAware: What


New Macular Degeneration Research: Will My AMD Affect Both Eyes? If So, How Soon Will That Happen?

Two questions asked most frequently by readers about age-related macular degeneration (AMD) involve (a) individual risk for the disorder and (b) the likelihood of eventual involvement of both eyes. In response, several recent studies have attempted to address these critically important questions: Data from the ongoing Blue Mountains Eye Study (BMES) and the


New Research from Google Labs: Using Machine Learning to Detect Diabetic Eye Disease

The highly regarded Research Labs at Google are charged with "tackling the most challenging problems in computer science and related fields," including eye care and ophthalmology. A groundbreaking project, announced in 2014 and still in development, was the creation of a prototype "smart" contact lens to monitor blood glucose levels continuously for people with diabetes.


Meet Joseph Fontenot, MD, CVLT: Be Informed and Proactive About Low Vision Services, Protect Yourself, and Always "Buyer Beware"

Joseph Fontenot,M.D., CLVT Dr. Joseph Fontenot is a medical doctor, Certified Low Vision Therapist, and Medical Director of Community Services for Vision Rehabilitation (CSVR), with offices in Alabama and Mississippi. He is also the current Chair of the American Academy of Ophthalmology's Vision Rehabilitation Committee. In that role,


Have Diabetes? Education, Guidance, and Support Are Essential

The American Diabetes Association celebrates American Diabetes Awareness every November and this year the theme is #This is Diabetes. The 2016 campaign seeks to showcase real-life stories of the 29 million Americans managing the day-to-day triumphs and challenges of diabetes to raise awareness and to create a sense of urgency about this public health concern. Their mission is to empower, educate, and support people living with diabetes in order to improve health outcomes and quality of life.


The Medicare Rights Center Answers Your Medicare Questions

by Joe Baker, Medicare Rights Center staff On October 15, open enrollment begins for Medicare recipients. This can be a very confusing time. You can get help from The Medicare Rights Center, a national, nonprofit consumer service organization. This organization works to ensure access to affordable health care for older adults and people with disabilities through counseling and advocacy, educational programs and public policy initiatives. The Center works tirelessly to ensure access to affordable health care for older adults and people with disabilities through its counseling and advocacy, educational programs, and public policy initiatives. Medicare Rights is the largest and most


African-American Patients: Highest Risk for Diabetic Retinopathy and Lowest Rates for Follow-Up Eye Care – What Kind of Education Is Needed?

A retina withdiabetic retinopathy An emerging body of diabetes, vision, and health care research indicates that significant disparities in the quality and equity of eye care exist throughout the United States, more specifically within the African American and Latino patient communities. This research includes an evaluation of the disparities in screening rates for diabetic retinopathy among minority patients, an examination of


A Powerful New Report from the National Academies of Sciences, Engineering, and Medicine: Making Eye and Vision Health an Imperative for All Americans

The National Academiesof Sciences, Engineering,and Medicine logo Several recent United States-based eye and vision research projects, including the Los Angeles Latino Eye Study and the Philadelphia Glaucoma Detection and Treatment Project, have highlighted significant disparities in the quality and equity of eye care throughout the country, including barriers within the health care and public


New Research Examines the Association Between Diabetic Eye Disease and Depression: Should Eye Doctors Be More Alert to Patients' Mental Health?

New diabetic retinopathy research from Australia and Singapore suggests that "the severity and progression of diabetic retinopathy can be a useful indicator to prompt the assessment of psychological well-being, particularly in individuals with other risk factors." The researchers further indicate that doctors who are treating adults with chronic disabling eye disease "should be alert and sensitive to potential indicators of depression such as sad mood, poor sleep and appetite, impaired concentration, and diminished


New Research Exploring Public Attitudes About Eye and Vision Health: Losing Vision Is Equal to Losing Hearing, Memory, Speech, or a Limb

New survey research from Johns Hopkins University and the University of Chicago that explores Americans' attitudes toward (a) the importance of eye health, (b) concerns about losing vision, (c) support for eye health research, and (d) awareness of eye diseases and risk factors has also revealed that the loss of eyesight is considered by many survey respondents to be "the worst ailment that could happen … relative to losing memory, speech, hearing, or a limb." According to the authors, "These findings emphasize the importance of focusing on the preservation of eye health and public support for vision research across all ethnic and racial groups in


New Research Examines the Risk of Serious Eye Infection After Eye Injection Treatments for Macular Degeneration and Diabetic Eye Disease

Although the injectable drugs Lucentis, Eylea, or Avastin have revolutionized the treatment of wet macular degeneration and diabetic eye


New Research Indicates Long-Term Positive Effects of Intensive Blood Sugar Control on the Progression of Diabetic Retinopathy

New diabetes and diabetic retinopathy research indicates that people with type 2 diabetes, who intensively controlled their blood sugar levels during the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Eye Study, cut their risk of diabetic retinopathy in half in a follow-up analysis, called the ACCORD Follow-on


An Award-Winning Optometric Student Essay: Ethical Issues in Low Vision Rehabilitation

The Association of Schools and Colleges of Optometry (ASCO) is the academic leadership organization committed to promoting excellence in optometric education. ASCO's activities cover a wide range of educational issues related to optometry, including applicant development and diversity, faculty and executive development, advocacy, and communications. ASCO also recognizes optometric student achievement through a number of annual awards, including the


New Research: The Number of Older Americans with Visual Impairment or Blindness Is Expected To Double By 2050

According to new demographic research addressing blindness, vision impairment, and low vision, the number of older Americans who have visual impairments or are blind is projected to double by 2050. This important – and urgent – research, entitled Visual Impairment and Blindness in Adults in the United States: Demographic and Geographic Variations from 2015 to 2050, has been published "online first" in the May 19, 2016 edition of JAMA


Understanding Low Vision Care and Low Vision Devices: Part 2 in a Series on Low Vision and Low Vision Services by Bryan Gerritsen, CLVT

Guest blogger Bryan Gerritsen is a certified low vision therapist (CLVT) and owner of Low Vision Rehabilitation Services, providing low vision services throughout Utah. He is also the author of An Overview of Low Vision Devices,


There is Hope; There is Help: Part 1 in a Series on Low Vision and Low Vision Services by Bryan Gerritsen, CLVT

Guest blogger Bryan Gerritsen is a certified low vision therapist (CLVT) and owner of Low Vision Rehabilitation Services, providing low vision services throughout Utah. He is also the author of An Overview of Low Vision Devices,


Researchers Identify a Mechanism that May Explain Why Some People Experience Accelerated Diabetic Retinopathy and Vision Loss

New diabetes and diabetic retinopathy research from Harvard Medical School, via Investigative Ophthalmology & Visual Science, the official journal of the Association for Research in Vision and Ophthalmology (ARVO), has demonstrated an association between a defective myogenic response – the increase or decrease in blood pressure that serves to regulate a consistent blood flow within the vessels of


Charles Bonnet Syndrome: Visual Hallucinations Are My Constant Companions by VisionAware Peer Advisor Sheila Rousey

Guest blogger and VisionAware Peer Advisor Sheila Rousey is an educator, assistive technology specialist, and certified braille transcriber. With a Master's degree in Special Education from Clemson University, Sheila has provided Interrelated Special Education Instruction in the public


New Research from Canada: Approximately One in Five Persons with Vision Loss Experience Visual Hallucinations

Charles Bonnet ("Bo-NAY") Syndrome (CBS) is a condition that causes vivid, complex, recurrent visual hallucinations, usually in older adults with later-life vision loss from eye conditions that can include macular degeneration, diabetic retinopathy, and


New Research Explained: Restoring Vision Following Long-Term Blindness: Prosthetic Vision and Considerations for Rehabilitation

During the past several years, there has been much "buzz" in the popular press about the capabilities of the so-called "bionic" eye, described variously as "miraculous," "restoring sight," and "letting me see again." At VisionAware, we have followed the development of "bionic" or "prosthetic" vision closely, avoiding hyperbole and striving to report factual, research-based information about the limitations of restored vision. Now, in this month's edition of the Journal of Vision Impairment & Blindness, two researchers who are pioneers in the study of prosthetic vision analyze the current state of the art in


New Research: Significant Disparities Exist in Screening Rates for Diabetic Retinopathy among Minority Patients

New diabetes research from the University of California at Los Angeles indicates that there is a pronounced disparity in diabetic retinopathy screening rates between Hispanic and African American patients. Compared with Hispanic patients, African American patients were screened 50% less often in the previous year, despite reporting similar barriers to screening, similar awareness that diabetes may lead to diabetic retinopathy, and the same likelihood of receiving physician recommendation for diabetic retinopathy


New Research: Stepped Care for Coping with Age-Related Vision Loss, Depression, and Anxiety

New research from Europe indicates that stepped care – a type of treatment that can offer self-help and "as needed" options for coping with age-related vision loss and depression – can offer promise in dealing with depression and anxiety in visually impaired older adults. Further, this stepped care approach (detailed below) could lead to standardized strategies for the screening, monitoring, treatment, and referral of visually impaired older adults with vision-related depression and anxiety. From the British Medical Journal (BMJ) The research, entitled


Our Readers Want to Know: Why Am I Having Visual Hallucinations Along with My Vision Loss?

Editor's note: One of the many benefits associated with an online information center and website, such as VisionAware, is the ability to track readers' search terms [i.e., information readers are seeking as they search the Internet]. Since the earliest days of VisionAware.org, and more so during the past year, the following questions appear consistently within our top searches: I'm seeing things that I know aren't there. What is wrong with me? I'm nervous because I see people in my house, but I know they're not really there. Why is this happening? An Answer from VisionAware <img src="http://www.afb.org/image.asp?ImageID=3758" alt="Engraving of Charles Bonnet in profile.


AFB Press Releases New Edition of Making Life More Livable: Simple Adaptations for Living at Home after Vision Loss

by Mary D'Apice, VisionAware Contributing Writer An interview with Maureen A. Duffy, CVRT, Author Making Life More Livable Agencies that provide services to people who are blind or visually impaired offer vision rehabilitation to the 5.3 million Americans over 65 with


New Survey: Less than Half of United States Adults with Diabetes Understand Their Risk for Vision Loss

A new survey released this month by Regeneron Pharmaceuticals, Inc. reveals that less than half of recently surveyed United States adults with diabetes recognize their risk for vision loss. Regeneron is a science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. [Please note: Regeneron Pharmaceuticals, Inc., which commissioned this survey, is also the developer of the injectable drug EYLEA,


New Research: Lucentis Is Effective in Treating Proliferative Diabetic Retinopathy and More Effective than Traditional Laser Treatment

Results from a new clinical trial have revealed that the injectable drug Lucentis is highly effective in treating proliferative diabetic retinopathy, a serious vision-related complication of diabetes. "These findings," said Dr. Paul Sieving, Director of the National Eye Institute (NEI), "provide crucial evidence for a safe and effective alternative to laser


Enrollment News about the New PIVOT Study: Patient-centric Innovative Vision Home Testing

The PIVOT Study (Patient-centric Innovative Vision HOme Testing) is a new clinical study that is being initiated to determine if persons with diabetic macular edema (DME) or wet age-related macular degeneration (wet AMD) can use the myVisionTrack™ (mVT™) mobile medical application (also called


Meet Doug Anzlovar and the New "Low Vision Focus @ Hadley" Program at The Hadley School for the Blind

Doug Anzlovar is the Vice President of Education and Training at The Hadley School for the Blind, where he serves as a member of the administrative team, oversees a 31-member faculty, is involved in curriculum decisions and policy development, and oversees the Low Vision Focus @ Hadley program. Prior to joining Hadley, Doug worked as a teacher of the visually impaired in the Chicago Public Schools for nearly 10 years. While at Walter Payton College Preparatory High School in Chicago, Doug developed a resource program for students with visual impairments and later became chair


Ways to Make Monitoring Blood Sugar Easier, More Accurate, and Less Costly: Part 5 in a Series

Audrey Demmitt, RN, BSN, is a nurse diabetic educator, VisionAware Peer Advisor, AFB Career Connect mentor, and author of the VisionAware multi-part blog series on diabetes and diabetes education. At age 25, Audrey was diagnosed with retinitis pigmentosa and continued to work as a nurse for 30 years with her visual impairment. She has worked as an Adjustment to Blindness


Exercising Safely With Diabetes: Part 4 in a Series

Audrey Demmitt, RN, BSN, is a nurse diabetic educator, VisionAware Peer Advisor, AFB Career Connect mentor, and author of the VisionAware multi-part blog series on diabetes and diabetes education. At age 25, Audrey was diagnosed with retinitis pigmentosa and continued to work as a nurse for 30 years with her visual impairment. She has worked as an Adjustment to Blindness


Healthy Eating with Diabetes: Part 3 in a Series

Audrey Demmitt, RN, BSN, is a nurse diabetic educator, VisionAware Peer Advisor, AFB Career Connect mentor, and author of the VisionAware multi-part blog series on diabetes and diabetes education. At age 25, Audrey was diagnosed with retinitis pigmentosa and continued to work as a nurse for 30 years with her visual impairment. She has worked as an Adjustment to Blindness


A New Protein Shows Promise for the Treatment and Perhaps Even Prevention of Diabetic Eye Disease

Although there have been a number of significant advances in the treatment of diabetic eye disease, including Avastin, Lucentis, and Eylea injections, this approach has not proven to be effective in preventing the development of diabetic eye disease and proliferative diabetic retinopathy (explained below).


Optogenetics: Can This Innovative Gene Therapy Treat Degenerative Retinal Disease and Possibly Restore Sight?

A research group of Swiss and German scientists has restored vision to mice with a condition similar to retinitis pigmentosa (RP) by introducing engineered light-sensing proteins into their eyes, via a process known as optogenetics. Optogenetics is a still-experimental treatment for a variety of blinding retinal disorders that uses gene therapy to enable retinal and brain cells to respond to light. According to the researchers, "… optogenetic gene therapy, which selectively introduces genes encoding light-sensitive proteins into surviving retinal cells to act as


Diabetes and the Significance of the A1c Test: Part 2 in a Series

Audrey Demmitt, RN, BSN, is a nurse diabetic educator, VisionAware Peer Advisor, AFB Career Connect mentor, and author of the VisionAware multi-part blog series on diabetes and diabetes education. At age 25, Audrey was diagnosed with retinitis pigmentosa and continued to work as a nurse for 30 years with her visual impairment. She has worked as an Adjustment to Blindness


Diabetes Education Can Help You Lower Your Blood Sugars and Reduce the Risk of Diabetic Retinopathy: Part 1 in a Series

Audrey Demmitt, RN, BSN, is a nurse diabetic educator, VisionAware Peer Advisor, AFB Career Connect mentor, and author of the VisionAware multi-part blog series on diabetes and diabetes education. At age 25, Audrey was diagnosed with retinitis pigmentosa and continued to work as a nurse for 30 years with her visual impairment. She has worked as an Adjustment to Blindness


New Research: African-Americans with Diabetes Experience the Highest Rates of Vision Loss

A new study has revealed that African-Americans with diabetes have higher rates of vision loss from diabetic macular edema (explained below) compared with other ethnic and racial groups – and inconsistent access to eye care and eye examinations is a likely contributor to this disparity. From JAMA Ophthalmology The research, entitled Prevalence of and Risk Factors for


New Research: Patients not Referred for Low Vision Services in a Timely and Efficient Manner

Last month, at the 2014 American Academy of Optometry Annual Meeting, a group of student researchers from the New England College of Optometry presented survey data that identified (a) patient barriers to low vision services and (b) the actions optometrists can take to improve the efficiency of referrals to low vision specialists. Their research revealed a discrepancy between


The FDA Approves Injectable Implant ILUVIEN for Treatment of Diabetic Macular Edema

On September 26, 2014, Alimera Sciences, Inc. announced that the United States Food and Drug Administration (FDA) approved Iluvien for the treatment of diabetic macular edema in persons who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Alimera Sciences, Inc., headquartered in Alpharetta,


Avastin Injection Dosages Can Vary Significantly When Prepared by Compounding Pharmacies

A new study has investigated the safety, sterility, and dosage consistency of Avastin, a lower-cost intravenous cancer drug that is used "off label," via eye injection, to treat a range of retinal disorders including age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.


In Clinical Trials: A Potential Self-Administered Treatment for Diabetic Macular Edema

Aerpio Therapeutics, Inc. is a new Cincinnati, Ohio-based biopharmaceutical company focused on developing new therapies for vascular [i.e., blood vessel] diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD). This week, Aerpio announced positive clinical trial results for


The FDA Approves EYLEA Injection for the Treatment of Diabetic Macular Edema

Some good news for individuals who have diabetes and associated diabetic macular edema: On July 29, 2014, the United States Food and Drug Administration (FDA) approved EYLEA (generic name aflibercept) for the treatment of diabetic macular edema. The recommended dosage is two milligrams (mg) every two


Google's Prototype "Smart Contact Lens": Measuring Blood Glucose Levels for People with Diabetes

Earlier this year, Google unveiled a prototype "smart" contact lens to monitor blood glucose levels contained in human tears. The Smart Contact Lens Project, which had been percolating in the top-secret Google X lab for several years, debuted a potential, although long-term, solution for effective blood glucose control in people with diabetes. January 2014: Google Unveils the Smart Contact Lens Here is an excerpt from the January 2014 announcement, via the official


Meet the Vision Institute and StreetLab: Vision Research, Simulations, and Education in Paris

During Vision Research Month, it gives me great pleasure to highlight the work of the Vision Institute of Paris and its subsidiary StreetLab. Both organizations are committed to ongoing vision research, with StreetLab featuring complementary and innovative outreach methods to enhance accessibility, inclusion, public awareness, and education. The Vision Institute of Paris (L'Institut de la Vision de Paris) Located in the center of Paris, the Vision Institute is an interdisciplinary research center that addresses eye diseases, vision loss, environmental modification, and daily living skills through the


New Research: Rethinking Charles Bonnet Syndrome and Visual Hallucinations

Charles Bonnet ("Bo-NAY") Syndrome (CBS) is a condition that causes vivid, complex, recurrent visual hallucinations, usually in older adults with later-life vision loss from eye conditions that can include macular degeneration, diabetic retinopathy, and glaucoma. The visual hallucinations associated with CBS can range from animated, colorful, dreamlike images to less complicated


Our Readers Want to Know: How Is a Vision Screening Different from a Comprehensive Eye Exam?

Editor's note: One of the many benefits associated with an online information center and website, such as VisionAware, is the ability to track readers' search terms [i.e., information readers are seeking as they search the Internet]. Since the earliest days of VisionAware.org, the following questions about eye exams consistently rank within the top information searches: How can I keep my eyes healthy and prevent eye disease? What is the difference between a full eye examination and a shorter vision screening? About Healthy Vision Month During


Could Glaucoma Actually Be "Diabetes of the Brain"? A New Hypothesis Says Maybe

A group of medical researchers from India is proposing the radical new hypothesis that glaucoma may indeed be diabetes of the brain. The research, entitled Glaucoma – Diabetes of the brain: A radical hypothesis about its nature and pathogenesis [i.e., the mechanisms that cause it], has been published in the May 2014 issue of Medical Hypotheses. Published by Elsevier Inc., Medical Hypotheses is a forum


New Adaptive Optics Technology Can Detect Very Early Microscopic Diabetes-Related Eye Damage

Researchers from the School of Optometry and the Department of Ophthalmology at Indiana University have developed new technology, based on the principles of adaptive optics, to detect the earliest warning signs of diabetic retinopathy. Previously, these microscopic changes were not detectable using standard diagnostic techniques. The research, entitled In vivo adaptive optics microvascular imaging in diabetic patients without clinically severe diabetic


Researchers in the United Kingdom Create Viable Retinal Cells via Inkjet Printing Technology

Here is some interesting – and startling – scientific news as we enter 2014: Researchers from the University of Cambridge in the United Kingdom have used inkjet printing technology to successfully print retinal cells. The results provide "proof of concept" that an inkjet printer can be used to print two types of retinal cells from adult rats: ganglion cells and glial cells. Ganglion cells are a type of nerve cell that is found in the retina. Glia are non-nerve cells that provide support and protection for neurons in the brain and nervous system. This


Our Readers Want to Know: What Is the Difference Between Hyperglycemia and Hypoglycemia?

Editor's note: One of the many benefits associated with an online information center and website, such as VisionAware, is the ability to track readers' search terms [i.e., information readers are seeking as they search the Internet]. Since the earliest days of VisionAware.org, the following questions about blood glucose levels and diabetes consistently rank within the five most popular searches: How do blood glucose levels relate to diabetes? What is the difference between hypoglycemia and hyperglycemia? An Answer from Debra Sokol-McKay, MS, CVRT, CDE This week, during


New Research to Curb Harmful Blood Vessel Growth in Macular Degeneration and Diabetic Retinopathy

Researchers working in conjunction with the University College London (UCL) Institute of Ophthalmology have discovered a protein of previously unknown function (leucine-rich alpha-2-glycoprotein 1, or LRG1), which has been found to contribute to the growth of the harmful bleeding/leaking blood vessels that accompany age-related macular degeneration and proliferative diabetic retinopathy. This research is in its earliest stages and has been


In Spain, Researchers Regenerate Retina in Mice: the Laboratory Results

Recently, I learned about a fascinating study in which researchers from the Center for Genomic Regulation (CRG) in Barcelona, Spain have identified a pathway that triggers the reprogramming and regeneration of retinal neurons in the eye; in addition, they have regenerated mouse retinal tissue through cell reprogramming This research is in its earliest stages and has been conducted only with laboratory mice. Nevertheless, the concept shows great promise for persons with retinal disease. The study, entitled


A New Low Vision Publication from the Council of Citizens with Low Vision International

The Council of Citizens with Low Vision International (CCLVI) has just published Insights into Low Vision, a compilation of tools, tips, techniques, and research updates for peer advocates, family members, professionals, and individuals with low vision. Here is more information about this much-needed publication from the CCLVI website: CCLVI's new publication, Insights into Low Vision … has articles by 26 authors, all nationally-known specialists in


VisionExchange: A Support Group for Support Group Leaders by Guest Blogger Polly Abbott, CVRT

In honor of Vision Rehabilitation Therapist (VRT) Appreciation Week (June 23-29), VisionAware is featuring the work of talented VRTs throughout the United States. Polly Abbott is a Certified Vision Rehabilitation Therapist (CVRT), an Orientation and Mobility Specialist with a background in education, and Director of Rehabilitation Services at Second Sense in Chicago,


A New Diabetes Training Course for Community Health Workers from the National Eye Institute

The National Eye Institute (NEI) has released the Diabetes and Healthy Eyes Toolkit, which includes a free interactive online training course for community health workers. The online course, which was developed by NEI's National Eye Health Education Program (NEHEP), teaches participants how to lead an educational session for people who have diabetes. The course uses animations, interactive features, and quizzes to provide information about the anatomy of the eye, the effects of


myVisionTrack: An At-Home App for Monitoring Eye Disease Receives FDA Clearance

myVisionTrack™ is a hand-held, prescription-only medical device, provided as an app for the iPhone 4S, that has received clearance by the United States Food and Drug Administration (FDA) on March 24, 2013 to be marketed as an at-home method for monitoring the progression of degenerative eye diseases, such as macular degeneration and diabetic retinopathy. The myVisionTrack™ medical device is produced by Vital Art and Science (VAS),


A New Low Vision Resource from the National Eye Institute

The National Eye Institute (NEI) has released a 20-page, full-color, large print booklet with companion videos, in support of Low Vision Awareness Month, February 2013. The booklet and videos were developed by NEI's National Eye Health Education Program (NEHEP). The mission of NEI, a part of the National Institutes of Health, is to "conduct and support research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health


Positive Phase III Clinical Trial Results for Totally Blind Persons with Sleep Disorders

On January 23, 2013, Vanda Pharmaceuticals, Inc. announced positive Phase III clinical trial results from the recently completed Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon (RESET) study; in addition, on December 18, 2012, Vanda announced positive Phase III clinical trial results from the Safety and Efficacy of Tasimelteon (SET) study. Tasimelteon is an experimental drug treatment for totally blind individuals with no light perception who experience a sleep problem called "Non-24-Hour Sleep-Wake Disorder." In the United States, this disorder affects approximately 65,000 totally blind


November—a Time of Thanksgiving

We know the end of October brought about very bad times for millions of people and that it is going to take a very long time to get back to normal. But as a nation we have lots to be thankful for, such as the opportunity coming up to vote as a free people, the wonderful generosity of people who have donated time and money to help those in need, and the sacrifices of our military personnel to help keep us safe and secure, to name just a few. We hope you will continue keep the storm victims in mind and, if you can, respond to requests for providing assistance. With that in mind, VisionAware has a section on


Charles Bonnet Syndrome: My Personal and Professional Journey

This past week, I found myself involved in an interesting Twitter discussion about Charles Bonnet ("Bo-NAY") Syndrome (CBS), a condition that causes vivid, complex, recurrent visual hallucinations, usually (but not solely) in older adults with later-life vision loss. The "visual hallucinations" associated with CBS can range from animated, colorful, dreamlike images to less complicated visions


More Follow-Up To the Coping with Vision Loss Study

As always, it's highly informative to follow up with VisionAware author Kaye Olson, the coordinator of the Coping with Vision Loss Study, which investigated the wide range of coping strategies used by adults and older adults who are blind, visually impaired, or have low vision. Following Up: The Field Responds Several weeks ago, I blogged about the follow-up


Documentary Film "Going Blind" To Have September Capitol Hill Screening for US Legislators

Meet filmmaker Joe Lovett, friend of VisionAware and producer/director of Going Blind: Coming out of the Dark about Vision Loss, a stunning and moving documentary film created to increase public awareness of blindness, vision loss, and the vision rehabilitation system. Going Blind is also Joe's personal story of his ongoing struggle with glaucoma and his sometimes-difficult journey through the "secret world," as he


The FDA Approves Lucentis for Diabetic Macular Edema

Here is excellent news for individuals who have diabetes and associated diabetic macular edema: On August 10, 2012, the United States Food and Drug Administration (FDA) approved Genetech's Lucentis (generic name ranibizumab) for the treatment of diabetic macular edema (DME). In its approval announcement, the FDA noted that Lucentis is for use in persons with "good diabetic sugar control" and is designed to be given once a month as an injection into the eye by a qualified health care professional. About Diabetic Macular Edema


Are Memory Problems Linked to Eye Disease and Diabetes?

Two recent studies suggest that memory loss and cognitive decline may be linked to (a) diabetes, (b) poor control of blood sugar levels by persons with diabetes, and/or (c) damage to retinal blood vessels, called retinopathy. What is Retinopathy? Retinopathy is a general term that describes damage to the retina, which is the thin, light-sensitive tissue that lines the inside surface of the eye. Nerve cells in the retina convert


The Joslin Diabetes Center's Incredible "50-Year Medalists"

Researchers at the The Joslin Diabetes Center and the Juvenile Diabetes Research Foundation (JDRF) have completed a study of 158 people who have lived with documented type 1 diabetes for 50 years or more, and who comprise a portion of the Joslin 50-Year Medalists cohort. The researchers concluded that a significant percentage of this unique group of patients


A New Website from the National Institutes of Health: Clinical Research Trials and You

From a press release from the National Institutes of Health (NIH): The National Institutes of Health has created a new website, NIH Clinical Research Trials and You, to help people learn more about clinical trials, why they matter, and how to participate. From the first cure of a solid tumor with chemotherapy to the use of nitroglycerin in response to heart attacks, clinical research trials – or research studies involving people – have played a vital role in improving health and quality of life for people around the


Follow Us:

Blog Archive Browse Archive

Join Our Mission

Help us expand our resources for people with vision loss.